Tejara Capital Ltd Acquires New Holdings in Enovis Corporation $ENOV

Tejara Capital Ltd purchased a new stake in shares of Enovis Corporation (NYSE:ENOV) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 31,100 shares of the company’s stock, valued at approximately $644,000. Tejara Capital Ltd owned about 0.05% of Enovis at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of ENOV. Dimensional Fund Advisors LP grew its position in Enovis by 1.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,971,545 shares of the company’s stock valued at $90,156,000 after buying an additional 51,201 shares in the last quarter. Rubric Capital Management LP acquired a new stake in shares of Enovis in the 3rd quarter worth approximately $83,435,000. Paradigm Capital Management Inc. NY lifted its stake in shares of Enovis by 70.2% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock worth $40,420,000 after acquiring an additional 732,917 shares during the period. River Road Asset Management LLC boosted its holdings in shares of Enovis by 3.2% in the fourth quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company’s stock valued at $39,621,000 after acquiring an additional 46,289 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its holdings in shares of Enovis by 38.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 1,045,360 shares of the company’s stock valued at $24,430,000 after acquiring an additional 287,687 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Price Performance

NYSE ENOV opened at $26.07 on Friday. Enovis Corporation has a 1 year low of $19.14 and a 1 year high of $34.28. The business’s fifty day moving average is $25.13 and its two-hundred day moving average is $24.14. The stock has a market capitalization of $1.50 billion, a P/E ratio of -1.35 and a beta of 1.34. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.00 and a current ratio of 1.98.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.05. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The business had revenue of $582.78 million during the quarter, compared to analyst estimates of $581.84 million. During the same period last year, the company posted $0.79 EPS. The company’s revenue was up 3.2% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, research analysts forecast that Enovis Corporation will post 3.15 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on ENOV shares. BTIG Research boosted their target price on Enovis from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Wells Fargo & Company lowered their price target on Enovis from $40.00 to $39.00 and set an “overweight” rating on the stock in a research report on Friday, August 7th. Zacks Research raised Enovis from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. Wall Street Zen lowered Enovis from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Weiss Ratings raised Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Enovis presently has a consensus rating of “Moderate Buy” and a consensus target price of $41.29.

Insider Buying and Selling

In other Enovis news, insider Oliver Engert bought 1,200 shares of the stock in a transaction on Thursday, June 11th. The shares were bought at an average price of $21.62 per share, with a total value of $25,944.00. Following the purchase, the insider directly owned 51,840 shares in the company, valued at $1,120,780.80. The trade was a 2.37% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last three months, insiders bought 4,200 shares of company stock worth $92,084. Company insiders own 2.90% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.